Bavarian Nordic is a vaccine company focused on developing and manufacturing vaccines for infectious diseases.
Bavarian Nordic received approval from the US Food and Drug Administration (FDA) for its Vimkunya chikungunya vaccine for individuals aged 12 and older. The vaccine, the first virus-like particle (VLP) single-dose vaccine for chikungunya, was approved based on phase 3 clinical trial results showing up to 97.8% of participants developed neutralizing antibodies within 21 days. The vaccine is expected to be available in the US in the first half of 2025, and the FDA awarded a Tropical Disease Priority Review Voucher to the company.1
Vimkunya aims to address chikungunya, a mosquito-borne disease affecting travel destinations. The vaccine will also be launched in European markets in 2025, pending final approval. In…